CellEKT©
Measure kinase target engagement and selectivity in native biological systems.
CellEKT is Omivera’s chemical proteomics platform for measuring kinase target engagement and selectivity directly in endogenous biological systems. Generate quantitative data across cell lines, primary cells, patient-derived models, and tissues to support confident drug discovery decisions.
What questions can CellEKT answer?
✓ Does my compound engage its intended kinase in a native biological system?
✓ How selective is my compound across the kinome?
✓ How much target engagement is achieved at a given concentration or dose?
✓ Does target engagement translate across biologically relevant models?
Model |
| Cell lines |
| Organoids |
| PBMCs |
| In vivo tissues |
| Clinical samples |
Coverage |
| 300–400 kinases |
| 300–400 kinases |
| Up to 350 kinases |
| 200+ kinases/tissue |
| Open for collaboration |
Best suited for |
|
Hit validation & lead optimization |
|
Disease-relevant biology |
|
Translational research |
|
Physiological target engagement |
1. The drug is added to disease-relevant living cells or organoids.
2. Patented kinase probes are added to the cells or organoids.
3. Mass spectrometry identifies and quantifies all labelled kinases.
4. Compare treated vs untreated cells to reveal drug-target engagement.
Flexible study designs
|
High-throughput profiling |
Quantitative dose-response |
|
Screen many compounds at a single concentration |
Profile selected compounds in a full dose response curve |
|
Rapid prioritization |
Lead optimization & candidate selection |
CellEKT helps you generate biologically relevant profiling data for lead optimization and preclinical planning.
It is built on proprietary kinase probe technology developed through years of chemical proteomics research.
→ Patented kinase probes
→ Broad kinome coverage
→ Peer-reviewed scientific validation
→ Ongoing platform development
Built on validated chemical proteomics expertise.
Big pharma collaboration
Omivera’s technology is being applied in collaboration with a large pharmaceutical company, supporting the translation of CellEKT from academic research into real drug discovery settings.
Cover > 90% of the kinome
CellEKT has been used to build a strong reference base of profiled kinases.
Published Validation Study
The CellEKT platform is supported by peer-reviewed research, giving teams a scientific basis for using the technology in kinase inhibitor profiling.